98%
921
2 minutes
20
Background: A shift in the proportions of blood immune cells is a hallmark of cancer development. Here, we investigated whether methylation-derived immune cell type ratios and methylation-derived neutrophil-to-lymphocyte ratios (mdNLRs) are associated with triple-negative breast cancer (TNBC).
Methods: Leukocyte subtype-specific unmethylated/methylated CpG sites were selected, and methylation levels at these sites were used as proxies for immune cell type proportions and mdNLR estimation in 231 TNBC cases and 231 age-matched controls. Data were validated using the Houseman deconvolution method. Additionally, the natural killer (NK) cell ratio was measured in a prospective sample set of 146 TNBC cases and 146 age-matched controls.
Results: The mdNLRs were higher in TNBC cases compared with controls and associated with TNBC (odds ratio (OR) range (2.66-4.29), all P < 1e-04). A higher neutrophil ratio and lower ratios of NK cells, CD4 + T cells, CD8 + T cells, monocytes, and B cells were associated with TNBC. The strongest association was observed with decreased NK cell ratio (OR range (1.28-1.42), all P < 1e-04). The NK cell ratio was also significantly lower in pre-diagnostic samples of TNBC cases compared with controls (P = 0.019).
Conclusion: This immunomethylomic study shows that a shift in the ratios/proportions of leukocyte subtypes is associated with TNBC, with decreased NK cell showing the strongest association. These findings improve our knowledge of the role of the immune system in TNBC and point to the possibility of using NK cell level as a non-invasive molecular marker for TNBC risk assessment, early detection, and prevention.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596937 | PMC |
http://dx.doi.org/10.1186/s13148-021-01196-1 | DOI Listing |
J Ultrasound Med
September 2025
Department of Ultrasound, Donghai Hospital Affiliated to Kangda College of Nanjing Medical University, Lianyungang, China.
Objective: The aim of this study is to evaluate the prognostic performance of a nomogram integrating clinical parameters with deep learning radiomics (DLRN) features derived from ultrasound and multi-sequence magnetic resonance imaging (MRI) for predicting survival, recurrence, and metastasis in patients diagnosed with triple-negative breast cancer (TNBC) undergoing neoadjuvant chemotherapy (NAC).
Methods: This retrospective, multicenter study included 103 patients with histopathologically confirmed TNBC across four institutions. The training group comprised 72 cases from the First People's Hospital of Lianyungang, while the validation group included 31 cases from three external centers.
Front Oncol
August 2025
General Hospital of Ningxia Medical University, Yinchuan, China.
Background: Breast cancer (BRCA) is the most prevalent cancer in women, with triple-negative breast cancer (TNBC) accounting for 15-20% of cases. TNBC is associated with higher rates of metastasis, recurrence, and poorer prognosis, underscoring the urgent need for new diagnostic and therapeutic strategies.
Methods: In this study, multiple public online platform, including UCSC Genome, UALCAN, Kaplan Meier plotter, DepMap and Single Cell Portal were used to detect the expression of EPHA2 in TNBC.
Clin Cancer Res
September 2025
University of Padua, Padova, Italy.
Purpose: To assess prognosis of ER-low expression and its dynamics in HER2- metastatic breast cancer (BC) and to compare sensitivity to nivolumab between ER-low and triple-negative (TN) BC.
Experimental Design: Two cohorts were analyzed: a multicenter cohort of 982 patients with HER2- metastatic BC, and one prospective cohort of 110 patients with ER<10%/HER2- metastatic BC enrolled in the TONIC trial (testing nivolumab). Endpoints were: overall survival (OS) and post-relapse survival (PRS) in the retrospective cohort; progression-free survival (PFS), OS, and clinical benefit rate (CBR) in the TONIC trial.
Eur J Breast Health
September 2025
Facultad de Ciencias Médicas, Universidad Privada del Este filial Ciudad del Este, Paraguay.
Objective: The () gene, initially linked to sperm motility, is differentially expressed in triple negative breast cancer (TNBC), suggesting a role in tumor progression and therapy resistance. To characterize expression in breast cancer and evaluate its association with clinicopathological features, survival, and treatment response as a translational biomarker.
Materials And Methods: Data from The Cancer Genome Atlas (1,087 patients), Sweden Cancerome Analysis Network-Breast (3,273 patients), and geodatabases were analyzed.
ACS Omega
August 2025
Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon 97239, United States.
Triple-negative breast cancer (TNBC), the most aggressive type of breast cancer, has high rates of metastasis and recurrence and represents 15-20% of diagnosed breast cancer cases. Most women with TNBC experience recurrence following curative treatment for early-stage breast cancer. We have identified CET022, a novel small molecule, and shown that it inhibits TNBC growth and clonogenic potential in multiple cell lines (MDA-MB-231, MDA-MB-468, 4T1, and EMT6).
View Article and Find Full Text PDF